• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Activella (Estradiol/Norethindrone Acetate) Tablets

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Activella (Estradiol/Norethindrone Acetate) Tablets

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Activella is a combination hormone replacement therapy (HRT) tablet containing both estrogen and progestin. 

    Activella is specifically indicated for moderate to severe vasomotor symptoms due to menopause and for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. 

    Activella is supplied as a tablet for oral administration. The tablet is administered once daily with a dosage of 1 mg of the estrogen (17beta-estradiol) and 0.5 mg of the progestin (norethindrone acetate).

    Clinical Trials

    The effects of Activella on Bone Mineral Density (BMD) was investigated in the U.S. and in Europe in two multi-center, placebo-controlled studies. Participants were all postmenopausal women with intact uteri and baseline BMD values for lumbar spine within two standard deviations of the mean in healthy young women. Patients were randomized to groups given different dosages of either estradiol alone, norethindrone alone, a combination of the two (Activella), or placebo. Treatment was supplemented with calcium (500-1000 mg/day). In the United States and European studies, the mean percentage change in BMD between Activella and placebo was 5.9% and 6.3%, respectively.

    Also, Activella yielded a statistically significant reduction in serum and urine markers of bone turnover. This effect was apparent after three months of treatment and was retained for the entire two-year treatment period.

    Side Effects

    Common side effects include:

    • Breast tenderness/pain
    • Upper respiratory tract infections
    • Headache
    • Postmenopausal bleeding

    Women who have been diagnosed with the following, should NOT take Activella:

    • Known or suspected pregnancy
    • Breast cancer
    • Estrogen- dependent neoplasia
    • Active deep vein thrombosis
    • Thromboembolic disorders or stroke
    • Undiagnosed genital bleeding
    • Liver dysfunction or disease
    • Hypersensitivity to any of the active ingredients in the drug

    Women who have had hysterectomies should NOT take Activella, as the existing data suggests that the combination therapy of estrogen and progestin may increase risk of glucose intolerance and less favorable effects on lipid metabolism in women without a uterus.

    Mechanism of Action

    Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) through a negative feedback mechanism, and estrogen replacement therapy acts to reduce the elevated levels of these hormones seen in postmenopausal women.

    Progestin compounds enhance cellular differentiation and generally oppose the actions of estrogens by decreasing estrogen receptor levels, increasing local metabolism of estrogens to less active metabolites, or inducing gene products that blunt cellular responses to estrogen. Progestins exert their effects in target cells by binding to specific progesterone receptors that interact with progesterone response elements in target genes. Progesterone receptors have been identified in the female reproductive tract, breast, pituitary, hypothalamus, and central nervous system. Progestins produce similar endometrial changes to those of the naturally occurring hormone progesterone.
    (From FDA Label)

    Additional Information

    Visit the Novo Nordisk Pharmaceuticals web site to learn more about Activella and about other products, research, and services provided by the company that developed this drug.

    Approval Date: 2000-04-01
    Company Name: Novo Nordisk
    Back to Listings

    Upcoming Events

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing